Edition:
United Kingdom

SAGE Therapeutics Inc (SAGE.OQ)

SAGE.OQ on NASDAQ Stock Exchange Global Market

122.32USD
9:00pm BST
Change (% chg)

$-1.51 (-1.22%)
Prev Close
$123.83
Open
$124.62
Day's High
$130.57
Day's Low
$121.51
Volume
177,482
Avg. Vol
165,765
52-wk High
$195.97
52-wk Low
$59.59

Summary

Name Age Since Current Position

Kevin Starr

55 2016 Independent Chairman of the Board

Jeffrey Jonas

65 2013 President, Chief Executive Officer, Director

Kimi Iguchi

55 2016 Chief Financial Officer, Treasurer

Anne Cook

56 2017 Senior Vice President, General Counsel, Secretary

Albert Robichaud

57 2011 Chief Scientific Officer

Michael Cloonan

47 2017 Chief Business Officer

Stephen Kanes

53 2013 Chief Medical Officer

Michael Cola

58 2014 Independent Director

James Frates

50 2014 Independent Director

Geno Germano

57 2016 Independent Director

Asha Nayak

47 2017 Independent Director

Steven Paul

67 2011 Independent Director

Biographies

Name Description

Kevin Starr

Mr. Kevin P. Starr is the Independent Chairman of the Board of Sage Therapeutics Inc. Mr. Starr has served as a member of our Board of Directors since September 2011. From October 2011 to August 2013, he also served as our interim Chief Executive Officer. In 2007, Mr. Starr co-founded Third Rock Ventures, a venture capital firm where he remains a partner. Mr. Starr served as the interim Chief Executive Officer of Decibel Therapeutics from October 2015 to July 2016. From 2003 to 2007, Mr. Starr undertook a number of entrepreneurial endeavors in the life science and entertainment industries. From 2001 to 2002, Mr. Starr served as chief operating officer of Millennium Pharmaceuticals, Inc. He also served as Millennium’s chief financial officer from 1998 to 2002. Mr. Starr currently serves on the board of directors of Alnylam Pharmaceuticals, Inc., PanOptica, Inc., Decibel Therapeutics, Inc. and MyoKardia, Inc. Mr. Starr received an M.S. in corporate finance from Boston College and a B.S./B.A. in mathematics and business from Colby College. Mr. Starr’s qualifications to serve on our Board of Directors include his executive management roles with responsibility over key financial and business planning functions and experience in the formation, development and business strategy of multiple start-up companies in the life sciences sector.

Jeffrey Jonas

Dr. Jeffrey M. Jonas, M.D. is the President, Chief Executive Officer and Director of Sage Therapeutics Inc. Dr. Jonas has served as our Chief Executive Officer and President and a member of our Board of Directors since August 2013. From 2012 to 2013, Dr. Jonas served as the President of the Regenerative Medicine Division of Shire plc, or Shire, and from 2008 to 2012 as Senior Vice President of Research and Development, Pharmaceuticals at Shire. From 2007 to 2008, Dr. Jonas served as the Executive Vice President of Ionis Pharmaceuticals, Inc., formerly known as ISIS Pharmaceuticals, Inc. and from 2006 to 2007 as Chief Medical Officer and Executive Vice President of Forest Laboratories, Inc. and from 1991 to 1996 in senior-level positions at Upjohn Laboratories. Dr. Jonas also founded AVAX Technologies, Inc. and SCEPTOR Industries, Inc., where he served as the Chief Executive Officer, President and a Director. Dr. Jonas has published more than 70 scientific papers and chapters, authored more than 100 books, scientific articles and abstracts, and has received numerous awards. Dr. Jonas received his B.A. from Amherst College and M.D. from Harvard Medical School. He completed a residency in psychiatry at Harvard Medical School, and he served as Chief Resident in psychopharmacology at McLean Hospital, Harvard Medical School. Dr. Jonas’ qualifications to sit on our Board of Directors include more than 20 years of experience on both the scientific and business sides of the pharmaceutical and healthcare industries, particularly in the Central Nervous System (CNS) field.

Kimi Iguchi

Ms. Kimi E. Iguchi is the Chief Financial Officer and Treasurer of Sage Therapeutics Inc .Ms. Iguchi joined SAGE as CFO in 2013, bringing both financial and operating strength from her senior management experience at Millennium, Biogen and emerging life science companies. Prior to joining SAGE, Kimi served as the Chief Operating Officer, North America, for Santhera Pharmaceuticals. Prior to that, she held the role of Vice President of Finance at Cyberkinetics Neurotechnology Systems. Previously, Kimi was the Senior Director of Financial Reporting and Analysis at Millennium Pharmaceuticals and the Senior Manager of External Reporting at Biogen, Inc. She also worked as a business assurance manager at ricewaterhouseCoopers LLP and started her career in chemistry-related positions at various Boston-based companies. Ms. Kimi holds a B.A. in chemistry from Drew University and an MBA from Northeastern University. She earned her CPA in Massachusetts.

Anne Cook

Ms. Anne Marie Cook is the Senior Vice President, General Counsel, Secretary of Sage Therapeutics, Inc. Ms. Cook was Senior Vice President and General Counsel of Sage Therapeutics, Inc. Ms. Cook joined SAGE as General Counsel in 2015. Before joining SAGE, Anne Marie served as Senior Vice President, General Counsel and Secretary at Aegerion Pharmaceuticals. Before that, she was a partner with Boston-based law firm Choate Hall & Stewart LLP (Choate), where she represented life science companies in structuring and negotiating strategic transactions such as joint ventures, collaborations, mergers and acquisitions and intellectual property. Additionally, she provided general legal support in connection with the research, development and commercialization of pharmaceutical products. Prior to joining Choate, she was Senior Vice President, Business & Corporate Development, General Counsel at ViaCell, Inc., and Chief Corporate Counsel at Biogen. Anne Marie holds a B.S. in biology from Tufts University and a J.D. from the University of Notre Dame Law School.

Albert Robichaud

Dr. Albert J. Robichaud, Ph.D. is a Chief Scientific Officer of Sage Therapeutics Inc. Dr. Robichaud joined SAGE as CSO in 2011, with more than 20 years of drug discovery experience focused primarily in the neuroscience arena. Most recently, he was Vice President of Chemistry and Pharmacokinetic Sciences at Lundbeck USA, where he was responsible for the drug discovery, analytical, computational and pharmacokinetics departments focused on synaptic transmission and neuroinflammation. Prior to Lundbeck, Al was Senior Director and Head of the Neuroscience Discovery Chemistry Department of Wyeth Research. During his tenure there, his group successfully delivered more than 15 drug candidates into clinical development in a broad range of neuroscience indications. Al has co-authored more than 125 manuscripts and abstracts, and is a co-inventor on 50 patents and patent applications. Al holds a B.S. in chemistry from Rensselaer Polytechnic Institute, a Ph.D. in organic chemistry from the University of California, Irvine and was an American Chemical Society postdoctoral fellow at Colorado State University.

Michael Cloonan

Mr. Michael Cloonan is the Chief Business Officer of Sage Therapeutics, Inc. Mr. Cloonan will lead Sage's Commercial, Portfolio and Program Management, Medical Affairs, and Corporate Development departments. Mr. Cloonan comes to Sage from Biogen, where he worked for 14 years. At Biogen, Mr. Cloonan most recently served as Senior Vice President, US Commercial, where he led a US affiliate with direct general manager responsibility for Sales, Marketing, Market Access, Patient Services and Commercial Operations. Previously, he held roles of increasing responsibility at Biogen, including Senior Vice President, Global Commercial Strategy; Vice President, Managing Director, Australia/New Zealand affiliate; and Vice President, Business Planning. Prior to Biogen, Mr. Cloonan worked at Bain & Company as a consultant specializing in healthcare. Mr. Cloonan received his M.B.A. from Darden Graduate School of Business Administration, University of Virginia and a B.A. from College of the Holy Cross.

Stephen Kanes

Dr. Stephen J. Kanes, M.D., Ph.D. is the Chief Medical Officer of Sage Therapeutics Inc. Dr. Kanes joined SAGE as CMO in 2013. Steve is a former practicing psychiatrist and previously served as the Executive Director/Therapeutic Area Clinical Director for the inflammation, neuroscience and respiratory GMED division of AstraZeneca Pharmaceuticals. At AstraZeneca, he also served as the Chair of the Neuroscience Safety Knowledge Group. During his time at AstraZeneca, Steve served as the Medical Science Senior Director for the neuroscience established brands and emerging anesthesia group product team and in other positions of increasing responsibility in the neuroscience discovery medicine, early and late development groups. Prior to joining AstraZeneca, he was a faculty member in the psychiatry department at the University of Pennsylvania School of Medicine, where he continues to serve as an adjunct assistant professor of psychiatry. Steve has authored or co-authored more than 30 peer-reviewed publications. He serves as an ad hoc reviewer for the journals Neuropsychopharmacology, American Journal of Medical Genetics and Biological Psychiatry. Steve received his B.A. from the University of Pennsylvania and both his Ph.D. and M.D. from State University of New York, Stony Brook. He completed his psychiatry residency at Yale-New Haven Medical Center and postdoctoral fellowship at the University of Pennsylvania.

Michael Cola

Mr. Michael F. Cola is an Independent Director of Sage Therapeutics, Inc. Mr. Cola has served as a member of our Board of Directors since September 2014. He currently serves as President and Chief Executive Officer of Aevi Genomic Medicine, Inc., formerly Medgenics, Inc. Prior to joining Aevi, from 2005 to 2012, he served as president of specialty pharmaceuticals at Shire plc, a global specialty pharmaceutical company. Previously from 2000 to 2005, Mr. Cola also served as a growth capital provider and president of the life sciences group for Safeguard Scientifics, Inc., where he served as Chairman and Chief Executive Officer of Clarient, Inc., and Chairman of Laureate Pharma, Inc. In addition, Mr. Cola has held senior positions in product development and commercialization at AstraMerck and AstraZeneca. Mr. Cola received a B.A. in biology and physics from Ursinus College and an M.S. in biomedical science from Drexel University. Mr. Cola also serves on the board of directors of Vanda Pharmaceuticals Inc. and serves as chairman for the board of governors of the Boys & Girls Clubs of Philadelphia. We believe Mr. Cola’s qualifications to sit on our Board of Directors include his extensive experience working for various pharmaceutical and biotechnology companies.

James Frates

Mr. James M. Frates is an Independent Director of Sage Therapeutics Inc. Mr. Frates has served as a member of our Board of Directors since May 2014. He is the Senior Vice President and Chief Financial Officer of Alkermes plc, having held that position since September 2011. From 2007 to 2011, Mr. Frates served as Senior Vice President and Chief Financial Officer of Alkermes, Inc. From 1998 to 2007, Mr. Frates served as Vice President, Chief Financial Officer and Treasurer of Alkermes, Inc. From 1996 to 1998, he was employed at Robertson, Stephens & Company, most recently as a Vice President in Investment Banking. Prior to that time, he was employed at Morgan Stanley & Co. From 2004 to 2009, Mr. Frates served on the board of directors of GPC Biotech AG, a biotechnology company, and was a national director of the Association of Bioscience Financial Officers from 2004 to 2009. Mr. Frates is also a Trustee of St. Paul’s School and The Roxbury Latin School. We believe Mr. Frates’ qualifications to sit on our Board of Directors include his leadership experience, financial expertise, business judgment and industry knowledge.

Geno Germano

Mr. Geno J. Germano is an Independent Director of Sage Therapeutics, Inc.. He served as President of Intrexon Corporation, a leader in engineering and industrialization of biology, from June 2016 to March 2017. As President, Mr. Germano was responsible for leading Intrexon’s management team and commercialization efforts utilizing the Intrexon’s technology platform for biologically-based solutions across a broad range of industries including health, consumer, energy, environment and food. Prior to joining Intrexon, from 2014 to February 2016. Mr. Germano was Group President of the Global Innovative Pharma Business of Pfizer Inc., where he led a growing global $14 billion business with market-leading medicines and an extensive portfolio of late-stage development candidates in several therapeutic areas including cardiovascular, metabolic disease, neuroscience, inflammation, immunology, and rare diseases. Mr. Germano was also Co-Chair of the Portfolio Strategy and Investment Committee at Pfizer, Inc. focused on maximizing the return on research and development investment across the Pfizer portfolio from 2013 to 2016. Previously, from 2009 through 2013, Mr. Germano served as President and General Manager of Pfizer’s Specialty Care and Oncology business units where he led commercial, medical, and post proof-of-concept pipeline strategy and development across global markets, as well as held responsibility for driving P&L growth and pipeline value through disciplined portfolio management. In addition, while in this role he directed the integration of Wyeth and Pfizer Specialty Care and Vaccines Businesses and developed top talent within the organization focusing on the leadership team. Prior to joining Pfizer from 1993 to 2009, Mr. Germano held numerous executive and leadership roles at Wyeth Pharmaceuticals including President of Wyeth U.S., where he was responsible for delivery of operational results across four business units, as well as President of its Global Pharmaceutical and Women’s Healthcare Business.

Asha Nayak

Dr. Asha Nayak, M.D., Ph.D, is Director of the company. She currently serves as chief medical officer at Intel Corporation where she guides its healthcare investment strategy and provides clinical and business leadership to Intel’s broad spectrum of healthcare programs. Dr. Nayak served as co-principal investigator on four clinical studies that demonstrated the value of Intel technologies in the areas of oncology and preventative cardiology. Before joining Intel, she was vice president at New Leaf Venture Partners, guiding its investments in the medical device sector. Earlier, Dr. Nayak created and led several new therapy programs at Medtronic. Now, and throughout her career, Dr. Nayak maintains an active clinical practice at the Stanford VA emergency department. She is the inventor on numerous patents and is published in several textbooks and peer-reviewed journals. Dr. Nayak holds an M.D. and Ph.D. in neuroscience from the University of Colorado and completed internal medicine residency and Biodesign Innovation Fellowship programs at Stanford University.

Steven Paul

Dr. Steven M. Paul, M.D. is an Independent Director of Sage Therapeutics Inc . Dr. Paul has served as a member of our Board of Directors since September 2011. Dr. Paul is currently the President and Chief Executive Officer of Voyager Therapeutics, Inc., having held that position since September 2014. Since September 2010, Dr. Paul has also served as a venture partner at Third Rock Ventures, LLC, or Third Rock Ventures, a life sciences venture capital firm focused on the formation, development and strategy of new companies. From 2011 to 2014, he was a professor of neuroscience, psychiatry and pharmacology at Weill Cornell Medical College. From 2003 to 2010, Dr. Paul, as the Executive Vice President of Eli Lilly and Company, or Eli Lilly, and President of Lilly Research Laboratories, was responsible for Eli Lilly’s overall research and development efforts—helping to expand Eli Lilly’s R&D efforts in oncology and biotechnology—resulting in a pipeline of approximately 70 new molecular entities. Dr. Paul spent 17 years at Eli Lilly, during which time he held several key leadership roles, including Vice President of Neuroscience (CNS) Research and Group Vice President of Discovery Research (all therapeutic areas) from 1993 to 2003. Prior to Eli Lilly, from 1988 to 1993 Dr. Paul served as Scientific Director of the National Institute of Mental Health (NIMH). Dr. Paul also served as Medical Director in the Commissioned Corps of the United States Public Health Service. Dr. Paul has been the recipient of many awards and honors, and has served on numerous committees and advisory boards. Dr. Paul has also authored or co-authored over 500 papers and book chapters. He is an elected fellow of the American Association for the Advancement of Science and a member of the Institute of Medicine of the National Academy of Sciences. Dr. Paul received his B.A. in Biology and Psychology from Tulane University, and his M.S. and M.D. degrees from the Tulane University School of Medicine.

Basic Compensation

Name Fiscal Year Total

Kevin Starr

747,793

Jeffrey Jonas

5,748,360

Kimi Iguchi

2,056,180

Anne Cook

2,450,750

Albert Robichaud

1,033,320

Michael Cloonan

10,043,700

Stephen Kanes

1,971,620

Michael Cola

731,103

James Frates

728,631

Geno Germano

716,132

Asha Nayak

902,666

Steven Paul

725,513
As Of  31 Dec 2017

Options Compensation